MedPath

A double-blind, multicentric, multinational randomised study to assess the effects of one year administration of 2 g per day of strontium ranelate versus marketed bisphosphonates in women with postmenopausal osteoporosis on bone microarchitecture as measured by high-resolution peripheral-quantitative computed tomography (p-QCT)

Not Applicable
Completed
Conditions
Post-menopausal osteoporosis
Musculoskeletal Diseases
Registration Number
ISRCTN82719233
Lead Sponsor
Institut de Recherches Internationales Servier (France)
Brief Summary

2010 results in: http://www.ncbi.nlm.nih.gov/pubmed/20512336

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
72
Inclusion Criteria

1. Women of at least 50 years old
2. Postmenopausal for at least five years
3. Osteoporosis

Exclusion Criteria

1. Body mass index (BMI) <18 or >30 kg/m^2
2. Skeletal disease
3. Severe malabsorption
4. Significant and evolutive hyperthyroidism

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath